vs
Side-by-side financial comparison of POPULAR, INC. (BPOP) and Edwards Lifesciences (EW). Click either name above to swap in a different company.
Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $835.8M, roughly 2.0× POPULAR, INC.). POPULAR, INC. runs the higher net margin — 29.4% vs 23.1%, a 6.3% gap on every dollar of revenue. Over the past eight quarters, POPULAR, INC.'s revenue compounded faster (25.1% CAGR vs 9.7%).
Popular, Inc., doing business as Banco Popular de Puerto Rico (BPPR) or simply as Banco Popular in Puerto Rico and the U.S. and British Virgin Islands, and as Popular Bank in the United States, is a full-service financial services conglomerate headquartered at Popular Center in the Milla de Oro financial district in the Hato Rey business center of San Juan, the capital municipality of the archipelago and island of Puerto Rico. Founded in 1893, it is the largest banking institution in Puerto R...
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
BPOP vs EW — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $835.8M | $1.6B |
| Net Profit | $245.7M | $380.7M |
| Gross Margin | — | 78.0% |
| Operating Margin | 44.1% | 1.8% |
| Net Margin | 29.4% | 23.1% |
| Revenue YoY | — | 16.7% |
| Net Profit YoY | 38.4% | 6.8% |
| EPS (diluted) | $3.78 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $835.8M | $1.6B | ||
| Q4 25 | $657.6M | $1.6B | ||
| Q3 25 | $646.5M | $1.6B | ||
| Q2 25 | $631.5M | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $590.8M | $1.4B | ||
| Q3 24 | $572.5M | $1.4B | ||
| Q2 24 | $568.3M | $1.4B |
| Q1 26 | $245.7M | $380.7M | ||
| Q4 25 | $233.9M | $91.2M | ||
| Q3 25 | $211.3M | $291.1M | ||
| Q2 25 | $210.4M | $333.2M | ||
| Q1 25 | — | $358.0M | ||
| Q4 24 | $177.8M | $385.6M | ||
| Q3 24 | $155.3M | $3.1B | ||
| Q2 24 | $177.8M | $366.3M |
| Q1 26 | — | 78.0% | ||
| Q4 25 | — | 78.1% | ||
| Q3 25 | — | 77.8% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 79.9% |
| Q1 26 | 44.1% | 1.8% | ||
| Q4 25 | 42.4% | 9.6% | ||
| Q3 25 | 38.2% | 19.8% | ||
| Q2 25 | 40.9% | 26.8% | ||
| Q1 25 | — | 27.9% | ||
| Q4 24 | 37.5% | 22.6% | ||
| Q3 24 | 34.5% | 25.9% | ||
| Q2 24 | 38.4% | 26.8% |
| Q1 26 | 29.4% | 23.1% | ||
| Q4 25 | 35.6% | 5.8% | ||
| Q3 25 | 32.7% | 18.7% | ||
| Q2 25 | 33.3% | 21.7% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | 30.1% | 27.8% | ||
| Q3 24 | 27.1% | 226.7% | ||
| Q2 24 | 31.3% | 26.7% |
| Q1 26 | $3.78 | $0.66 | ||
| Q4 25 | $3.51 | $0.16 | ||
| Q3 25 | $3.14 | $0.50 | ||
| Q2 25 | $3.09 | $0.56 | ||
| Q1 25 | — | $0.61 | ||
| Q4 24 | $2.51 | $0.65 | ||
| Q3 24 | $2.16 | $5.13 | ||
| Q2 24 | $2.46 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $17.6M | — |
| Stockholders' EquityBook value | $6.3B | — |
| Total Assets | $76.1B | — |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $4.2B | ||
| Q3 25 | — | $3.8B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $3.9B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $2.0B |
| Q1 26 | $17.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.2B | $10.3B | ||
| Q3 25 | $6.1B | $10.2B | ||
| Q2 25 | $6.0B | $10.5B | ||
| Q1 25 | — | $10.1B | ||
| Q4 24 | $5.6B | $10.0B | ||
| Q3 24 | $5.8B | $9.5B | ||
| Q2 24 | $5.4B | $7.4B |
| Q1 26 | $76.1B | — | ||
| Q4 25 | $75.3B | $13.7B | ||
| Q3 25 | $75.1B | $13.3B | ||
| Q2 25 | $76.1B | $13.5B | ||
| Q1 25 | — | $13.0B | ||
| Q4 24 | $73.0B | $13.1B | ||
| Q3 24 | $71.3B | $13.0B | ||
| Q2 24 | $72.8B | $10.1B |
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BPOP
| Net Interest Income | $670.2M | 80% |
| Noninterest Income | $165.6M | 20% |
EW
Segment breakdown not available.
